Impact of MET expression on outcome in BRAF V600E/K advanced melanoma
Adrian M. Jubb, Antoni Ribas, Jeffrey Alan Sosman et al. · Histopathology · 2013
AIMS: Preclinical data suggest that signalling through the HGF-MET pathway may confer resistance to BRAF inhibition in BRAF(V600E/K) melanoma. Therefore, blockade of HGF-MET signalling might be a valid therapeutic strategy, in combination with BRAF inhibition, in BRAF(V600E/K) melanoma. The aim of this study was to investigate the clinical relevance of these observations by evaluating the survival impact of MET expression in patients with BRAF(V600E/K) advanced melanoma treated with vemurafenib. METHODS AND RESULTS: Formalin-fixed tissue blocks were obtained of tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF(V600E/K) melanoma. Immunohistochemistry for MET (SP44 rabbit monoclonal antibody) was performed with a highly validated assay and clinically validated scoring system. Pretreatment MET expression was frequent at the ≥1 + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the ≥2 + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival. CONCLUSIONS: MET is expressed in a proportion of BRAF(V600E/K) advanced melanomas. Further analyses on appropriately powered subsets are needed to determine the prognostic and predictive significance of MET in vemurafenib-treated melanoma.
Cited by 15 works. doi:10.1111/his.12169
Authors
- Adrian M. Jubb
- Antoni Ribas
- Jeffrey Alan Sosman
- Grant A. McArthur
- Yibing Yan
- Sandra Rost
- Sherry S. Zhao
- Hartmut Koeppen
References
- Mutations of the BRAF gene in human cancer
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Distinct Sets of Genetic Alterations in Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma